Healthcare / BiotechnologyNasdaqCM
$3.76
-0.05 (-1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-47.3M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$290M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-56.3%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-45.6M · FCF $-62.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | $0.00 | $0.00 | — | — | — |
| Net Income | $-45.6M | $-45.6M | $-36.2M | $-116.5M | $-88.0M | $-34.5M | $-22.8M | $-16.0M | $-14.1M | $-13.1M | $-5.7M | $-45.1M | $-23.3M | $-15.7M | $-9.6M |
| EBITDA | $-82.9M | $-82.9M | $-70.2M | $-42.6M | $-39.4M | — | $-18.5M | $-16.0M | $-14.0M | $-13.1M | $-5.1M | — | — | — | — |
| EPS | -0.52 | -0.52 | -0.66 | -3.74 | -6.16 | -2.33 | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.05 | 0.01 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 8.44 | 8.44 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-62.3M | $-62.3M | $-47.3M | $-39.5M | $-28.4M | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -56.3% | -56.3% | -57.9% | -1616.8% | -104.5% | -21.0% | -12.0% | -169.2% | -97.1% | -67.4% | 209.3% | -1620.7% | -22.5% | 28.5% | 24.2% |
| Valuation | |||||||||||||||
| P/B | 3.79 | 3.79 | 3.75 | 6.25 | 0.49 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | 21.2% | 21.2% | 82.4% | 39.3% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+25.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.66 → -0.52
Residual
+25.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.